Foghorn Therapeutics (FHTX) to Release Earnings on Monday

Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.30) per share and revenue of $4.96 million for the quarter.

Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.13. The business had revenue of $2.86 million for the quarter, compared to the consensus estimate of $8.56 million. On average, analysts expect Foghorn Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Foghorn Therapeutics Stock Up 1.9 %

Shares of NASDAQ FHTX traded up $0.08 on Friday, reaching $4.24. 108,884 shares of the company's stock traded hands, compared to its average volume of 139,003. The business's 50 day simple moving average is $4.05 and its two-hundred day simple moving average is $5.42. The company has a market cap of $235.79 million, a price-to-earnings ratio of -2.21 and a beta of 3.16. Foghorn Therapeutics has a 12 month low of $2.94 and a 12 month high of $10.25.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. JMP Securities reiterated a "market outperform" rating and issued a $9.00 price target on shares of Foghorn Therapeutics in a research note on Wednesday. Citizens Jmp initiated coverage on shares of Foghorn Therapeutics in a report on Wednesday, April 23rd. They set a "mkt outperform" rating and a $9.00 price target on the stock. Citigroup initiated coverage on shares of Foghorn Therapeutics in a research report on Wednesday, April 23rd. They set an "outperform" rating for the company. B. Riley initiated coverage on shares of Foghorn Therapeutics in a report on Thursday, January 30th. They issued a "buy" rating and a $10.00 price objective for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $13.00 target price on shares of Foghorn Therapeutics in a research note on Wednesday. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $12.13.

About Foghorn Therapeutics

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.